# Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

Study · id `cardio:ct-nct01890421` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01890421](<https://clinicaltrials.gov/study/NCT01890421>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01890421

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 426 participants.

## Technical summary

Registry record NCT01890421. Allocation not applicable; no masking; primary purpose diagnostic. Start 2013-07-19 (actual); primary completion 2015-04-10 (actual). Results posted on 2018-05-16.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Phase 3
- Enrolled: 426 participants (enrolled count; ClinicalTrials.gov record NCT01890421, source copy `cardio:ctgov-nct01890421-2018-05-16`, retrieved 2026-10-26)
- Started: 2013-07-19 (actual) (ClinicalTrials.gov record NCT01890421, source copy `cardio:ctgov-nct01890421-2018-05-16`, retrieved 2026-10-26)
- Primary completion: 2015-04-10 (actual) (ClinicalTrials.gov record NCT01890421, source copy `cardio:ctgov-nct01890421-2018-05-16`, retrieved 2026-10-26)
- Completion: 2017-08-31 (actual) (ClinicalTrials.gov record NCT01890421, source copy `cardio:ctgov-nct01890421-2018-05-16`, retrieved 2026-10-26)
- Results first posted: 2018-05-16 (ClinicalTrials.gov record NCT01890421, source copy `cardio:ctgov-nct01890421-2018-05-16`, retrieved 2026-10-26)
- Countries: United States; France; Germany; New Zealand; South Korea; Switzerland; United Kingdom (ClinicalTrials.gov record NCT01890421, source copy `cardio:ctgov-nct01890421-2018-05-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01890421-2018-05-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
- Acronym: GadaCAD 1
- Condition: Coronary Artery Disease
- Intervention (Drug): Gadobutrol (Gadovist, Gadavist, BAY86-4875)
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

## Provenance

Content hash: dc23e51b289123c6dd2387ee614f77497a161691a905f55ec2b7a6efe09909db
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
